Latest clinical study may shut door on secretin as autism drug

01/6/2004 | NYTimes.com

Repligen announced its latest clinical trial of the drug secretin has failed to prove the efficacy of using it to treat autism. The decision, following the largest and most definitive trial of the drug, casts doubt on whether secretin will ever become a treatment for the childhood disease.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Finance Manager - ENT
Medtronic
Jacksonville, FL
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA